Literature DB >> 18751836

An unusual case of granulomatous lung disease. A clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Deborah Alpert1, Douglas B Flieder, Doruk Erkan, Anne R Bass.   

Abstract

Entities:  

Year:  2006        PMID： 18751836      PMCID： PMC2488176          DOI： 10.1007/s11420-006-9009-0

Source DB:  PubMed          Journal:  HSS J        ISSN： 1556-3316


× No keyword cloud information.
  17 in total

Review 1.  Treatment of sarcoidosis -- from a basic science point of view.

Authors:  D R Moller
Journal:  J Intern Med       Date:  2003-01       Impact factor: 8.989

2.  Infliximab for refractory sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2001-03       Impact factor: 0.670

3.  Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.

Authors:  A M Yee; M B Pochapin
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

4.  Treatment of therapy-resistant sarcoidosis with adalimumab.

Authors:  José Luis Callejas-Rubio; Norberto Ortego-Centeno; Lourdes Lopez-Perez; Maria Nicolas Benticuaga
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

5.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

6.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  W J Sandborn; S B Hanauer; S Katz; M Safdi; D G Wolf; R D Baerg; W J Tremaine; T Johnson; N N Diehl; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

Review 7.  Pulmonary sarcoidosis.

Authors:  Robert P Baughman
Journal:  Clin Chest Med       Date:  2004-09       Impact factor: 2.878

8.  Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.

Authors:  Kai U Ulbricht; Matthias Stoll; Janine Bierwirth; Torsten Witte; Reinhold E Schmidt
Journal:  Arthritis Rheum       Date:  2003-12

Review 9.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 10.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.